Overview A Phase 1 Study of NM6603 in Advanced Solid Tumors Status: RECRUITING Trial end date: 2026-02-28 Target enrollment: Participant gender: Summary This study is to assess the MTD and RP2D of NM6603 in adult patients with advanced solid tumors.Phase: PHASE1 Details Lead Sponsor: NucMito Pharmaceuticals Co. Ltd.